Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
United Therapeutics (DE:UTH)
FRANKFURT:UTH
United Therapeutics (UTH) Stock Price & Analysis
2 Followers
UTH Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€189.80 - €235.40
Previous Close€219.9
Volume0.00
Average Volume (3M)23.00
Market Cap
€10.50B
Enterprise Value€8.34B
Total Cash (Recent Filing)$2.99B
Total Debt (Recent Filing)$700.00M
Price to Earnings (P/E)N/A
Beta0.33
Next Earnings
May 01, 2024EPS Estimate
€5.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding47,058,545
10 Day Avg. Volume8
30 Day Avg. Volume23
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)1.89
Price to Sales (P/S)16.58
Price to Cash Flow (P/CF)18.40
P/FCF Ratio33.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.58
Enterprise Value/Gross Profit4.03
Enterprise Value/Ebitda6.14
Forecast
1Y Price Target
€270.16Price Target Upside22.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
United Therapeutics News
PremiumCompany Announcements
United Therapeutics Announces $1 Billion Stock Buyback Plan
PremiumCompany Announcements
United Therapeutics Sues FDA Over Liquidia’s Drug Expansion
Bulls Say, Bears Say
Bulls Say
Financial HealthUnited Therapeutics' 4Q23 total revenues were above consensus estimates, marking the 3rd consecutive revenue beat quarter.
Market ExpansionThe Tyvaso franchise is expected to expand into new treatment areas, which could significantly grow its market.
Strategic InitiativesUTHR's revenue estimates for the upcoming fiscal year are above consensus, indicating confidence in the company's financial performance.
Bears Say
FDA And Market ExclusivityLegal disputes with the FDA and delayed regulatory decisions pose risks to the company's market exclusivity for its products.
Financial PerformanceRevenue declines for established products such as Remodulin and Orenitram may signal weakening financial performance.
Legal And Competitive ChallengesOngoing litigation and the threat of increased competition could undermine the market position of key products like Tyvaso.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
0.78% Other Institutional Investors
99.22% Public Companies and
Individual Investors
UTH FAQ
What was United Therapeutics’s price range in the past 12 months?
United Therapeutics lowest stock price was €189.80 and its highest was €235.40 in the past 12 months.
What is United Therapeutics’s market cap?
Currently, no data Available
When is United Therapeutics’s upcoming earnings report date?
United Therapeutics’s upcoming earnings report date is May 01, 2024 which is in 8 days.
How were United Therapeutics’s earnings last quarter?
United Therapeutics released its earnings results on Feb 21, 2024. The company reported €4.107 earnings per share for the quarter, beating the consensus estimate of €4.035 by €0.072.
Is United Therapeutics overvalued?
According to Wall Street analysts United Therapeutics’s price is currently Undervalued.
Does United Therapeutics pay dividends?
United Therapeutics does not currently pay dividends.
What is United Therapeutics’s EPS estimate?
United Therapeutics’s EPS estimate is €5.46.
How many shares outstanding does United Therapeutics have?
Currently, no data Available
What happened to United Therapeutics’s price movement after its last earnings report?
United Therapeutics reported an EPS of €4.107 in its last earnings report, beating expectations of €4.035. Following the earnings report the stock price went down -0.809%.
Which hedge fund is a major shareholder of United Therapeutics?
Among the largest hedge funds holding United Therapeutics’s share is Farallon Capital Management, L.L.C.. It holds United Therapeutics’s shares valued at 105M.
---
United Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€270.16 (22.86% Upside)
€270.16 (22.86% Upside)
Blogger Sentiment
Bullish
DE:UTH Sentiment 88%
Sector Average 69%
Sector Average 69%
Insider Transactions
Sold Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
2.15%
12-Months-Change
Fundamentals
Return on Equity
18.27%
Trailing 12-Months
Asset Growth
18.47%
Trailing 12-Months
Company Description
United Therapeutics
United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. The firm also involves in the research and development of new indications and delivery devices for its product, and for the organ transplantation-related technologies. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.
---
UTH Company Deck
---
UTH Earnings Call
Q4 2024
0:00 / 0:00
---
UTH Revenue Breakdown
53.01% Tyvaso
21.26% Remodulin
15.44% Orenitram
8.55% Unituxin
1.75% Other
---
UTH Stock 12 Months Forecast
Average Price Target
€270.16
▲(22.86% Upside)
Technical Analysis
Best Analysts Covering UTH
1 Year
1 Year Success Rate
24/28 ratings generated profit
1 Year Average Return
+18.15%
reiterated a buy rating 3 months ago
Copying Eun Yang's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +18.15% per trade.
---